Skip to main content

Immune Signatures for Therapy Stratification in Major Mood Disorders

Objective

Objective: MOODSTRATIFICATION brings together 11 partners (psychiatrists, immunologists, epidemiologists, industry) from 7 countries stratifying patients with a major depressive episode on the basis of leukocyte immune profiles. The immune profiles were found in two previous EU projects, which also delivered the novel concept, that T cell defects with episodes of chronic mild inflammation are a causal factor for a large part of mood disorders. The immune profiles determine therapy choice with (combinations of) conventional and novel therapies with immune modulators (e.g. anti-inflammatory and T cell enforcement therapies). On the basis of recent data we expect that the present poor response rates of about 50% to anti-depressant therapy will improve considerably to 80-90%. Mood disorders are complex diseases with a high prevalence (12-20%) and are the second highest contributor to the number of years lived with disability worldwide.
Work plan: MOODSTRATIFICATION firstly uses the large data sets and biobank of the two previous EU projects to further refine the already found immune profiles. Therefore the proposal further integrates existing and newly collected multidimensional, longitudinal clinical and laboratory data (-omics, FACS and serum multi-analytes) from these projects for further immune network analysis and computational modelling also taking female-male differences into account. Technologies to easily determine the immune profiles (a relatively small multi-analyte panel, Q-PCR kits on PAXGENE material) will together with industries be developed. Thereafter the efficacy of two novel T cell enforcing therapeutic approaches and the new concept of depression stratification on the basis of the immune profiles will be validated in three clinical proof-of-principle studies. Various national and international patient associations will be actively involved.
Novelty: This is the first lab-based therapy stratification in psychiatry made ready for the clinic.

Call for proposal

H2020-SC1-2017-Two-Stage-RTD
See other projects for this call

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 066 250

Participants (11)

WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
Germany
EU contribution
€ 428 750
Address
Schlossplatz 2
48149 Muenster
Activity type
Higher or Secondary Education Establishments
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 101 250
Address
Geschwister Scholl Platz 1
80539 Muenchen
Activity type
Higher or Secondary Education Establishments
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU contribution
€ 623 500
Address
Oude Markt 13
3000 Leuven
Activity type
Higher or Secondary Education Establishments
ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands
EU contribution
€ 471 750
Address
Hanzeplein 1
9713 GZ Groningen
Activity type
Higher or Secondary Education Establishments
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France
EU contribution
€ 688 125
Address
3 Avenue Victoria
75000 Paris
Activity type
Research Organisations
OSPEDALE SAN RAFFAELE SRL
Italy
EU contribution
€ 486 562,50
Address
Via Olgettina 60
20132 Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITAET ULM
Germany
EU contribution
€ 411 500
Address
Helmholtzstrasse 16
89081 Ulm
Activity type
Higher or Secondary Education Establishments
PRONTO DIAGNOSTICS LTD
Israel
EU contribution
€ 460 000
Address
Kiryat Atidim Building 3 2Nd Entrance
6158002 Tel Aviv
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ADVANCED PRACTICAL DIAGNOSTICS
Belgium
EU contribution
€ 446 500
Address
Raadsherenstraat 3
2300 Turnhout
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
AARHUS UNIVERSITET
Denmark
EU contribution
€ 480 500
Address
Nordre Ringgade 1
8000 Aarhus C
Activity type
Higher or Secondary Education Establishments
ILTOO PHARMA
France
EU contribution
€ 299 062,50
Address
47/83 Boulevard De L'hopital
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)